Melanoma - Recent advances in Immune-Checkpoint Inhibitors
This module is intended for medical oncologists interested in the underlying research behind metastatic melanoma therapies and management of the most common associated treatment side-effects. Included within this 45 minute module are: summaries of landmark trials in the field of melanoma, associated published commentaries, and relevant case-based scenarios with response feedback.
Learning objectives:
Review the outcomes of seminal publications and clinical trials that have led the changes in management for metastatic melanoma
Anticipate the most common and serious side effects of Immune-Checkpoint Inhibitors
Identify the best management options for side effects of melanoma therapy
This program was supported by educational grants from GlaxoSmithKline and Bristol-Myers Squibb.
You must have an MDcme.ca account and be logged in to register for this course
Credits
(up to) 0.75 credit hours
Expiry Date
This course expires on Thursday, January 31, 2019
Maintenance of Certification (Section 3) This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Office of Professional & Educational Development, Faculty of Medicine, Memorial University. You may claim a maximum of 0.75 hours (credits are automatically calculated).
Scientific Committee:
Dr. Kathryn Roth (Scientific Committee Chair), MD, FRCPC Assistant Professor, Department of Otolaryngology, Western University, London, ON
Dr. Scott Ernst, MD, FRCPC Division Head, Medical Oncology, Department of Oncology, Western University, London, ON
Dr. Alex Hammond, MD, BSC, MBBCH, ABRT, FRCPC Professor, Department of Oncology, Western University, London, ON
Michael Brock, MSc Educational Developer, Schulich School of Medicine & Dentistry, Western University, London, ON
Michael Murray, MSc Medical Writer, Schulich School of Medicine & Dentistry, Western University, London, ON